Surgical systems biology and personalized longitudinal phenotyping in critical care

Personalized Medicine

Volumn 9, Issue 6, 2012, Pages 593-608

  Muirhead, Laura J ^a   Kinross, James ^a   Fitzmaurice, Thomas S ^a   Takats, Zoltan ^b   Darzi, Ara ^a   Nicholson, Jeremy K ^b  

^a ST MARY S HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

metabolic phenotyping; microbiome; risk stratification; surgery; systems biology

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; MICRORNA; MICRORNA 25; MICRORNA 92A; PARACETAMOL; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

BACTERIAL METABOLISM; BARIATRIC SURGERY; BLEEDING; BODY MASS; BREAST CANCER; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CARDIOPULMONARY HEMODYNAMICS; CLINICAL DECISION MAKING; COLORECTAL CANCER; COMORBIDITY; DRUG METABOLISM; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HIGH RISK PATIENT; HUMAN; IN VIVO STUDY; INJURY; INJURY SEVERITY; INTENSIVE CARE; INTESTINE FLORA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUTRITIONAL STATUS; OPERATION DURATION; PERSONALIZED MEDICINE; PHENOTYPE; PHYLOGENY; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; PROTON NUCLEAR MAGNETIC RESONANCE; RESUSCITATION; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SPINAL CORD INJURY; SULFATION; SURGEON; SURGERY; SURGICAL RISK; SYSTEMS BIOLOGY;

EID: 84865477284     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.12.70     Document Type: Review

References (119)

1. Nicholson JK. Global systems biology, personalized medicine and molecular epidemiology. Mol. Syst. Biol. 2, 52 (2006
2. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29(11), 1181-1189 (1999
3. Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell 134(5), 714-717 (2008
4. Clayton TA, Lindon JC, Cloarec O et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440(7087), 1073-1077 (2006
5. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: A platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 1(2), 153-161 (2002 (Pubitemid 41646523)
6. Bengmark S. Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut 42(1), 2-7 (1998 (Pubitemid 28228378)
7. Gill SR, Pop M, Deboy RT et al. Metagenomic analysis of the human distal gut microbiome. Science 312(5778), 1355-1359 (2006 (Pubitemid 43839542)
8. Lederberg J. Infectious history. Science 288(5464), 287-293 (2000
9. Dethlefsen L, Mcfall-Ngai M, Relman DA. An ecological and evolutionary perspective on human-microbe mutualism and disease. Nature 449(7164), 811-818 (2007 (Pubitemid 47598621)
10. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000 (Pubitemid 30046295)
11. Ashida S, Orloff MS, Bebek G et al. Integrated analysis reveals critical genomic regions in prostate tumor microenvironment associated with clinicopathologic phenotypes. Clin. Cancer Res. 18(6), 1578-1587 (2012
12. Nishida N, Nagahara M, Sato T et al. Microarray analysis of colorectal cancer stromal tissue reveals upregulation of two oncogenic microRNA clusters. Clin. Cancer Res. 18(11), 3054-3070 (2012
13. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Eng. J. Med. 359(17), 1757-1765 (2008
14. Wu CC, Chen HC, Chen SJ et al. Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics 8(2), 316-332 (2008
15. Xue H, Lu B, Zhang J et al. Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J. Proteome Res. 9(1), 545-555 (2010
16. Osako T, Iwase T, Kimura K et al. Intraoperative molecular assay for sentinel lymph node metastases in early stage breast cancer: A comparative analysis between one-step nucleic acid amplification whole node assay and routine frozen section histology. Cancer 117(19), 4365-4374 (2011
17. Manolio TA. Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 363(2), 166-176 (2010
18. Kim H, Ramsay E, Lee H, Wahl S, Dionne RA. Genome-wide association study of acute post-surgical pain in humans. Pharmacogenomics 10(2), 171-179 (2009
19. Anderson CA, Boucher G, Lees CW et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat. Genet. 43(3), 246-252 (2011
20. Snyder TM, Khush KK, Valantine HA, Quake SR. Universal noninvasive detection of solid organ transplant rejection. Proc. Natl Acad. Sci. USA 108(15), 6229-6234 (2011
21. Anjum A, von Allmen R, Greenhalgh R, Powell JT. Explaining the decrease in mortality from abdominal aortic aneurysm rupture. Br. J. Surg. 99(5), 637-645 (2012
22. Spadaccio C, Di Domenico F, Perluigi M et al. Serum proteomics in patients with diagnosis of abdominal aortic aneurysm. Cardiovasc. Pathol. 21(4), 283-290 (2012
23. Kuhls DA, Malone DL, McCarter RJ, Napolitano LM. Predictors of mortality in adult trauma patients: The physiologic trauma score is equivalent to the Trauma and Injury Severity Score. J. Am. Coll. Surg. 194(6), 695-704 (2002 (Pubitemid 34633632)
24. Sutherland A, Thomas M, Brandon RA et al. Development and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis. Crit. Care 15(3), R149 (2011
25. Lapar DJ, Rosenberger LH, Walters DM et al. Severe traumatic head injury affects systemic cytokine expression. J. Am. Coll. Surg. 214(4), 478-486; discussion 486-478 (2012
26. Garcia-Miguel FJ, Serrano-Aguilar PG, Lopez-Bastida J. Preoperative assessment. Lancet 362(9397), 1749-1757 (2003 (Pubitemid 37468329)
27. Gouvas N, Tan E, Windsor A, Xynos E, Tekkis PP. Fast-track vs standard care in colorectal surgery: A meta-analysis update. Int. J. Colorectal Dis. 24(10), 1119-1131 (2009
28. Wilson RJ, Davies S, Yates D, Redman J, Stone M. Impaired functional capacity is associated with all-cause mortality after major elective intra-abdominal surgery. Br. J. Anaesth. 105(3), 297-303 (2010
29. What is the point of surgery? Lancet 376(9746), 1025 (2010
30. Wikoff WR, Anfora AT, Liu J et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl Acad. Sci. USA 106(10), 3698-3703 (2009
31. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124(4), 837-848 (2006 (Pubitemid 43261456)
32. Hartman AL, Lough DM, Barupal DK et al. Human gut microbiome adopts an alternative state following small bowel transplantation. Proc. Natl Acad. Sci. USA 106(40), 17187-17192 (2009
33. Zhang H, Dibaise JK, Zuccolo A et al. Human gut microbiota in obesity and after gastric bypass. Proc. Natl Acad. Sci. USA 106(7), 2365-2370 (2009
34. Kinross JM, Alkhamesi N, Barton RH et al. Global metabolic phenotyping in an experimental laparotomy model of surgical trauma. J. Proteome Res. 10, 277-287 (2010
35. Whelan K, Judd PA, Tuohy KM, Gibson GR, Preedy VR, Taylor MA. Fecal microbiota in patients receiving enteral feeding are highly variable and may be altered in those who develop diarrhea. Am. J. Clin. Nutr. 89(1), 240-247 (2009
36. Mai V, Greenwald B, Morris JG Jr, Raufman JP, Stine OC. Effect of bowel preparation and colonoscopy on post-procedure intestinal microbiota composition. Gut 55(12), 1822-1823 (2006 (Pubitemid 44893588)
37. Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS ONE 5(3), e9836 (2010
38. Vesper BJ, Jawdi A, Altman KW, Haines GK 3rd, Tao L, Radosevich JA. The effect of proton pump inhibitors on the human microbiota. Curr. Drug. Metab. 10(1), 84-89 (2009
39. Roller M, Rechkemmer G, Watzl B. Prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis modulates intestinal immune functions in rats. J. Nutr. 134(1), 153-156 (2004 (Pubitemid 38057439)
40. Woodard GA, Encarnacion B, Downey JR et al. Probiotics improve outcomes after Roux-en-Y gastric bypass surgery: A prospective randomized trial. J. Gastrointest. Surg. 13(7), 1198-1204 (2009
41. Reddy BS, Macfie J, Gatt M, Larsen CN, Jensen SS, Leser TD. Randomized clinical trial of effect of synbiotics, neomycin and mechanical bowel preparation on intestinal barrier function in patients undergoing colectomy. Br. J. Surg. 94(5), 546-554 (2007 (Pubitemid 46732236)
42. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: Human gut microbes associated with obesity. Nature 444(7122), 1022-1023 (2006 (Pubitemid 46018512)
43. Yap IK, Brown IJ, Chan Q et al. Metabolome-wide association study identifies multiple biomarkers that discriminate north and south Chinese populations at differing risks of cardiovascular disease: intermap study. J. Proteome Res. 9(12), 6647-6654 (2010
44. Wang Z, Klipfell E, Bennett BJ et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472(7341), 57-63 (2011
45. Kinross JM, Darzi AW, Nicholson JK. Gut microbiome-host interactions in health and disease. Genome Med. 3(3), 14 (2011
46. Swann JR, Want EJ, Geier FM et al. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc. Natl Acad. Sci. USA 108(Suppl. 1), 4523-4530 (2011
47. Jia W, Li H, Zhao L, Nicholson JK. Gut microbiota: A potential new territory for drug targeting. Nat. Rev. Drug Discov. 7(2), 123-129 (2008 (Pubitemid 351194060)
48. Bozzetti F, Gianotti L, Braga M, Di Carlo V, Mariani L. Postoperative complications in gastrointestinal cancer patients: The joint role of the nutritional status and the nutritional support. Clin. Nutr. 26(6), 698-709 (2007 (Pubitemid 350082492)
49. Stratton RJ, Elia M. Who benefits from nutritional support: What is the evidence? Eur. J. Gastroenterol. Hepatol. 19(5), 353-358 (2007 (Pubitemid 46596686)
50. Marik PE, Zaloga GP. Immunonutrition in high-risk surgical patients: A systematic review and analysis of the literature. JPEN J. Parenter. Enteral Nutr. 34(4), 378-386 (2010
51. Schwegler I, Von Holzen A, Gutzwiller JP, Schlumpf R, Muhlebach S, Stanga Z. Nutritional risk is a clinical predictor of postoperative mortality and morbidity in surgery for colorectal cancer. Br. J. Surg. 97(1), 92-97 (2010
52. Kuppinger D, Hartl WH, Bertok M et al. Nutritional screening for risk prediction in patients scheduled for abdominal operations. Br. J. Surg. 99(5), 728-737 (2012
53. Palmer C, Bik EM, Digiulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. PLoS Biology 5(7), e177 (2007
54. Biagi E, Nylund L, Candela M et al. Through ageing, and beyond: Gut microbiota and inflammatory status in seniors and centenarians. PLoS ONE 5(5), e10667 (2010
55. Nicholson JK, Lindon JC. Systems biology: Metabonomics. Nature 455(7216), 1054-1056 (2008
56. Somashekar BS, Kamarajan P, Danciu T et al. Magic angle spinning NMR-based metabolic profiling of head and neck squamous cell carcinoma tissues. J. Proteome Res. 10(11), 5232-5241 (2011
57. Li M, Song Y, Cho N et al. An HR-MAS MR metabolomics study on breast tissues obtained with core needle biopsy. PLoS ONE 6(10), e25563 (2011
58. Balog J, Szaniszlo T, Schaefer KC et al. Identification of biological tissues by rapid evaporative ionization mass spectrometry. Anal. Chem. 82(17), 7343-7350 (2010
59. Chan EC, Koh PK, Mal M et al. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS)J. Proteome Res. 8(1), 352-361 (2009
60. Miura D, Fujimura Y, Yamato M et al. Ultrahighly sensitive in situ metabolomic imaging for visualizing spatiotemporal metabolic behaviors. Anal. Chem. 82(23), 9789-9796 (2010
61. Croxatto A, Prod'hom G, Greub G. Applications of MALDI-TOF mass spectrometry in clinical diagnostic microbiology. FEMS Microbiol. Rev. 36(2), 380-407 (2012
62. Madhavan S, Gusev Y, Harris M et al. G-DOC: A systems medicine platform for personalized oncology. Neoplasia 13(9), 771-783 (2011
63. Rezzi S, Ramadan Z, Fay LB, Kochhar S. Nutritional metabonomics: Applications and perspectives. J. Proteome Res. 6(2), 513-525 (2007 (Pubitemid 46340155)
64. Nicholson JK, Wilson ID: OPINION: Understanding 'global' systems biology: Metabonomics and the continuum of metabolism. Nat. Rev. Drug Discov. 2(8), 668-676 (2003 (Pubitemid 37361770)
65. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl Acad. Sci. USA 106(34), 14728-14733 (2009
66. Osman D, Ridel C, Ray P et al. Cardiac filling pressures are not appropriate to predict hemodynamic response to volume challenge. Crit. Care Med. 35(1), 64-68 (2007 (Pubitemid 46035678)
67. Courtney DM, Neumar RW, Venkatesh AK et al. Unique characteristics of emergency care research: Scope, populations, and infrastructure. Acad. Emerg. Med. 16(10), 990-994 (2009
68. Beekley AC. Damage control resuscitation: A sensible approach to the exsanguinating surgical patient. Crit. Care Med. 36(Suppl. 7), S267-S274 (2008
69. Holcomb JB, Jenkins D, Rhee P et al. Damage control resuscitation: Directly addressing the early coagulopathy of trauma. J. Trauma 62(2), 307-310 (2007
70. Chen L, Reisner AT, Gribok A, Reifman J. Exploration of prehospital vital sign trends for the prediction of trauma outcomes. Prehosp. Emerg. Care 13(3), 286-294 (2009
71. Raum MR, Nijsten MW, Vogelzang M et al. Emergency trauma score: An instrument for early estimation of trauma severity. Crit. Care Med. 37(6), 1972-1977 (2009
72. Mao H, Wang H, Wang B et al. Systemic metabolic changes of traumatic critically ill patients revealed by an NMR-based metabonomic approach. J. Proteome Res. 8(12), 5423-5430 (2009
73. Ghosh S, Hill DW, Petty NM et al. Statistical approach to metabonomic analysis of rat urine following surgical trauma. J. Chemometrics 20, 87-98 (2006
74. Jiang H, Peng J, Zhou ZY et al. Establishing (1)H nuclear magnetic resonance based metabonomics fingerprinting profile for spinal cord injury: A pilot study. Chin. Med. J. (Engl.) 123(17), 2315-2319 (2010
75. Cohen MJ, Serkova NJ, Wiener-Kronish J, Pittet JF, Niemann CU. 1H-NMR-based metabolic signatures of clinical outcomes in trauma patients - beyond lactate and base deficit. J. Trauma 69(1), 31-40 (2010
76. Demssie YN, Jawaheer J, Farook S, New JP, Syed AA. Metabolic outcomes 1 year after gastric bypass surgery in obese people with Type 2 diabetes. Med. Princ. Pract. 21(2), 125-128 (2012
77. Adams TD, Gress RE, Smith SC et al. Long-term mortality after gastric bypass surgery. N. Eng. J. Med. 357(8), 753-761 (2007 (Pubitemid 47295642)
78. Ashrafian H, Ahmed K, Rowland SP et al. Metabolic surgery and cancer: Protective effects of bariatric procedures. Cancer 117(9), 1788-1799 (2011
79. Calvani R, Miccheli A, Capuani G et al. Gut microbiome-derived metabolites characterize a peculiar obese urinary metabotype. Int. J. Obes. (Lond.) 34(6), 1095-1098 (2010
80. Mutch DM, Fuhrmann JC, Rein D et al. Metabolite profiling identifies candidate markers reflecting the clinical adaptations associated with Roux-en-Y gastric bypass surgery. PLoS ONE 4(11), e7905 (2009
81. Li JV, Ashrafian H, Bueter M et al. Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut 60(9), 1214-1223 (2011
82. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N. Engl. J. Med. 350(22), 2239-2246 (2004
83. Holmström B, Johansson M, Bergh A, Stenman UH, Hallmans G, Stattin P. Prostate specific antigen for early detection of prostate cancer: Longitudinal study. BMJ 339, b3537 (2009
84. Jansen FH, Roobol M, Jenster G, Schroder FH, Bangma CH. Screening for prostate cancer in 2008 II: The importance of molecular subforms of prostate-specific antigen and tissue kallikreins. Eur. Urol. 55(3), 563-574 (2009
85. Klee EW, Bondar OP, Goodmanson MK et al. Candidate serum biomarkers for prostate adenocarcinoma identified by mRNA differences in prostate tissue and verified with protein measurements in tissue and blood. Clin. Chem. 58(3), 599-609 (2012
86. Ploussard G, de la Taille A. Urine biomarkers in prostate cancer. Nat. Rev. Urol. 7(2), 101-109 (2010
87. Wu T, Giovannucci E, Welge J, Mallick P, Tang WY, Ho SM. Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: A meta-analysis. Br. J. Cancer 105(1), 65-73 (2011
88. Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA, El-Serag HB. Level of alpha-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 9(11), 989-994 (2011
89. Sherman M. The resurrection of alphafetoprotein. J. Hepatol. 52(6), 939-940 (2010
90. Debruyne EN, Delanghe Jr. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: New aspects and applications. Clin. Chim. Acta 395(1-2), 19-26 (2008
91. Bachtiar I, Santoso JM, Atmanegara B et al. Combination of alpha-1-acid glycoprotein and alpha-fetoprotein as an improved diagnostic tool for hepatocellular carcinoma. Clin. Chim. Acta 399(1-2), 97-101 (2009
92. Sterling RK, Jeffers L, Gordon F et al. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 7(1), 104-113 (2009
93. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful? Clin. Chem. 47(4), 624-630 (2001 (Pubitemid 32275803)
94. Fletcher RH. Carcinoembryonic antigen. Ann. Intern. Med. 104(1), 66-73 (1986 (Pubitemid 16182780)
95. Roessler M, Rollinger W, Palme S et al. Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin. Cancer Res. 11(18), 6550-6557 (2005 (Pubitemid 41338994)
96. Wallin U, Glimelius B, Jirstrom K et al. Growth differentiation factor 15: A prognostic marker for recurrence in colorectal cancer. Br. J. Cancer 104(10), 1619-1627 (2011
97. Sturgeon CM, Duffy MJ, Walker G. The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: The pivotal role of the clinical laboratory. Ann. Clin. Biochem. 48(Pt 4), 295-299 (2011
98. Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: A systematic review and meta-analysis. Eur. J. Radiol. 71(1), 164-174 (2009
99. Skates SJ, Menon U, Macdonald N et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J. Clin. Oncol. 21(Suppl. 10), S206-S210 (2003).
100. Menon U, Gentry-Maharaj A, Jacobs I. Ovarian cancer screening and mortality. JAMA 306(14), 1544; author reply 1544-1545 (2011
101. Menon U, Gentry-Maharaj A, Hallett R et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: Results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)Lancet Oncol. 10(4), 327-340 (2009
102. Urban N, Thorpe JD, Bergan LA et al. Potential role of HE4 in multimodal screening for epithelial ovarian cancer. J. Natl Cancer Inst. 103(21), 1630-1634 (2011
103. Wang Q, Li D, Zhang W, Tang B, Li QQ, Li L. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses. Int. J. Biol. Markers 26(4), 262-273 (2011
104. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur. J. Surg. Oncol. 33(3), 266-270 (2007 (Pubitemid 46488663)
105. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J. Gastroenterol Hepatol. 19(2), 182-186 (2004 (Pubitemid 38253358)
106. Matsubayashi H, Canto M, Sato N et al. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res. 66(2), 1208-1217 (2006 (Pubitemid 43165992)
107. Koopmann J, Fedarko NS, Jain A et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol. Biomarkers Prev. 13(3), 487-491 (2004 (Pubitemid 38737477)
108. Simeone DM, Ji B, Banerjee M et al. CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 34(4), 436-443 (2007 (Pubitemid 46725785)
109. Eguia V, Gonda TA, Saif MW. Early detection of pancreatic cancer. JOP 13(2), 131-134 (2012
110. Dahhan T, Jamil M, Al-Tarifi A, Abouchala N, Kherallah M. Validation of the APACHE IV scoring system in patients with severe sepsis and comparison with the APACHE II system. Crit. Care 13(1), 511 (2009
111. Vincent JL, Moreno R. Clinical review: Scoring systems in the critically ill. Crit. Care 14(2), 207 (2010
112. Zimmerman JE, Kramer AA, McNair DS, Malila FM. Acute Physiology and Chronic Health Evaluation (APACHE) IV: Hospital mortality assessment for today's critically ill patients. Crit. Care Med. 34(5), 1297-1310 (2006
113. Costa e Silva VT, De Castro I, Liano F, Muriel A, Rodriguez-Palomares JR, Yu L. Performance of the third-generation models of severity scoring systems (APACHE IV, SAPS 3 and MPM-III) in acute kidney injury critically ill patients. Nephrology 26(12), 3894-3901 (2011
114. Hariharan S, Zbar A. Risk scoring in perioperative and surgical intensive care patients: A review. Curr. Surg. 63(3), 226-236 (2006 (Pubitemid 43832533)
115. Brooks MJ, Sutton R, Sarin S. Comparison of Surgical Risk Score, POSSUM and p-POSSUM in higher-risk surgical patients. Br. J. Surg. 92(10), 1288-1292 (2005 (Pubitemid 41475242)
116. Park JS, KimS H, Sheen SS, Jeong SM, Lee YJ. Effectiveness of the PRISM III score for predicting mortality in pediatric intensive care neurologic patients. Crit. Care 2(Suppl. 1), 161 (1998
117. Peres Bota D, Melot C, Lopes Ferreira F, Nguyen Ba V, Vincent JL. The Multiple Organ Dysfunction Score (MODS) versus the Sequential Organ Failure Assessment (SOFA) score in outcome prediction. Intensive Care Med. 28(11), 1619-1624 (2002 (Pubitemid 36002511)
118. Pettila V, Pettila M, Sarna S, Voutilainen P, Takkunen O. Comparison of Multiple Organ Dysfunction Scores in the prediction of hospital mortality in the critically ill. Crit. Care Med. 30(8), 1705-1711 (2002 (Pubitemid 34879578)
119. Moreno RP, Metnitz PG, Almeida E et al. SAPS 3 - from evaluation of the patient to evaluation of the intensive care unit. Part 2: Development of a prognostic model for hospital mortality at ICU admission. Intensive Care Med. 31(10), 1345-1355 (2005). (Pubitemid 41437728)